Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate) CAMBRIDGE, Mass., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced detailed results from the Phase 3 EVOLVE-MS-2 study demonstrating the improved patient-assessed...

New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years TECFIDERA consistently maintained low levels of disease activity with no increased risk in adverse events over a decade of treatmentLatest interim data from Phase 3 EVOLVE-MS-1 trial show Biogen and...

New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis Diroximel fumarate significantly reduced disease activity in newly diagnosed relapsing multiple sclerosis (MS) patients and those previously treated with interferons or glatiramer acetate Data show...

Biogen To Present Data At AAN Highlighting Its Innovative Marketed Treatments And Investigational Pipeline Programs For Complex Neurodegenerative Diseases Data demonstrate that pre-symptomatic infants with SMA treated with SPINRAZA® (nusinersen) over three years achieved motor milestones that are more consistent with normal childhood...

Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis DUBLIN, Ireland and CAMBRIDGE, Mass., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA)...